Suppr超能文献

新型 F-18 标记可逆放射性配体的合成及 Autoradiography 用于单胺氧化酶 B 的检测。

Synthesis and Autoradiography of Novel F-18 Labeled Reversible Radioligands for Detection of Monoamine Oxidase B.

机构信息

Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm 17176, Sweden.

GE Healthcare Pharmaceutical Diagnostics, Little Chalfont HP8 4SP, United Kingdom.

出版信息

ACS Chem Neurosci. 2020 Dec 16;11(24):4398-4404. doi: 10.1021/acschemneuro.0c00631. Epub 2020 Dec 7.

Abstract

Monoamine oxidase B (MAO-B) is an important enzyme regulating the levels of monoaminergic neurotransmitters. Selective MAO-B inhibitors have been labeled with carbon-11 or fluorine-18 to visualize the localization of MAO-B by positron emission tomography (PET) and thereby have been useful for studying neurodegenerative diseases. The aim of this study was to develop promising fluorine-18 labeled reversible MAO-B PET radioligands and their biological evaluation by autoradiography. Radiolabeling was achieved by classical one-step fluorine-18 nucleophilic substitution reaction. The stability and radiochemical yield was analyzed with HPLC. All five fluorine-18 labeled compounds were tested in human whole hemisphere autoradiography experiments. Five compounds (GEH200439, GEH200448, GEH200449, GEH200431A, and GEH200431B) were successfully radiolabeled with fluorine-18, and the incorporation yield of the fluorination reactions varied from 10 to 45% depending on the compound. The radiochemical purity was higher than 99% for all at the end of synthesis. Radioligands were found to be stable, with a radiochemical purity of >99% in a sterile phosphate buffered saline (pH = 7.4) over the duration of the study. The ARG binding density of only F-GEH200449 was consistent with known MAO-B expression in the human brain. Radiolabeling of five new fluorine-18 MAO-B reversible inhibitors was successfully accomplished. Compound F-GEH200449 binds specifically to MAO-B postmortem brain and could be a potential candidate for PET investigation.

摘要

单胺氧化酶 B(MAO-B)是调节单胺能神经递质水平的重要酶。已用碳-11 或氟-18 标记选择性 MAO-B 抑制剂,通过正电子发射断层扫描(PET)来可视化 MAO-B 的定位,从而有助于研究神经退行性疾病。本研究旨在开发有前途的氟-18 标记的可逆 MAO-B PET 放射性配体,并通过放射自显影对其进行生物学评估。放射性标记是通过经典的一步氟-18 亲核取代反应实现的。使用 HPLC 分析了稳定性和放射化学产率。在人类整个脑半球放射自显影实验中测试了所有五种氟-18 标记化合物。成功地用氟-18 标记了五种化合物(GEH200439、GEH200448、GEH200449、GEH200431A 和 GEH200431B),根据化合物的不同,氟代反应的掺入产率从 10%到 45%不等。在合成结束时,所有产物的放射化学纯度均高于 99%。研究期间,在无菌磷酸盐缓冲盐水(pH = 7.4)中,放射性配体稳定,放射化学纯度>99%。只有 F-GEH200449 的 ARG 结合密度与已知的人类大脑中的 MAO-B 表达一致。成功地完成了五种新的氟-18 MAO-B 可逆抑制剂的放射性标记。化合物 F-GEH200449 特异性结合死后大脑中的 MAO-B,可能是 PET 研究的潜在候选物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2bb5/7747220/a1cb7a7e3c5b/cn0c00631_0001.jpg

相似文献

1
Synthesis and Autoradiography of Novel F-18 Labeled Reversible Radioligands for Detection of Monoamine Oxidase B.
ACS Chem Neurosci. 2020 Dec 16;11(24):4398-4404. doi: 10.1021/acschemneuro.0c00631. Epub 2020 Dec 7.
5
In Vivo and In Vitro Characterization of a Novel MAO-B Inhibitor Radioligand, 18F-Labeled Deuterated Fluorodeprenyl.
J Nucl Med. 2016 Feb;57(2):315-20. doi: 10.2967/jnumed.115.161083. Epub 2015 Nov 19.
6
PET Evaluation of the Novel F-18 Labeled Reversible Radioligand [F]GEH200449 for Detection of Monoamine Oxidase-B in the Non-Human Primate Brain.
ACS Chem Neurosci. 2023 Sep 6;14(17):3206-3211. doi: 10.1021/acschemneuro.3c00332. Epub 2023 Aug 16.
8
Monoamine oxidase B inhibitor, selegiline, reduces F-THK5351 uptake in the human brain.
Alzheimers Res Ther. 2017 Mar 31;9(1):25. doi: 10.1186/s13195-017-0253-y.
9
F-SMBT-1: A Selective and Reversible PET Tracer for Monoamine Oxidase-B Imaging.
J Nucl Med. 2021 Feb;62(2):253-258. doi: 10.2967/jnumed.120.244400. Epub 2020 Jul 9.
10
Synthesis and preclinical evaluation of [F]FSL25.1188, a reversible PET radioligand for monoamine oxidase-B.
Bioorg Med Chem Lett. 2019 Jul 1;29(13):1624-1627. doi: 10.1016/j.bmcl.2019.04.040. Epub 2019 Apr 27.

引用本文的文献

1
PET imaging of neuroinflammation: any credible alternatives to TSPO yet?
Mol Psychiatry. 2025 Jan;30(1):213-228. doi: 10.1038/s41380-024-02656-9. Epub 2024 Jul 13.
2
PET Evaluation of the Novel F-18 Labeled Reversible Radioligand [F]GEH200449 for Detection of Monoamine Oxidase-B in the Non-Human Primate Brain.
ACS Chem Neurosci. 2023 Sep 6;14(17):3206-3211. doi: 10.1021/acschemneuro.3c00332. Epub 2023 Aug 16.
3
Imaging of Reactive Astrogliosis by Positron Emission Tomography.
Front Neurosci. 2022 Feb 8;16:807435. doi: 10.3389/fnins.2022.807435. eCollection 2022.

本文引用的文献

1
Synthesis and preclinical evaluation of [F]FSL25.1188, a reversible PET radioligand for monoamine oxidase-B.
Bioorg Med Chem Lett. 2019 Jul 1;29(13):1624-1627. doi: 10.1016/j.bmcl.2019.04.040. Epub 2019 Apr 27.
2
Classics in Neuroimaging: Development of PET Tracers for Imaging Monoamine Oxidases.
ACS Chem Neurosci. 2019 Apr 17;10(4):1867-1871. doi: 10.1021/acschemneuro.9b00081. Epub 2019 Feb 21.
3
Indole-Substituted Benzothiazoles and Benzoxazoles as Selective and Reversible MAO-B Inhibitors for Treatment of Parkinson's Disease.
ACS Chem Neurosci. 2017 Jul 19;8(7):1519-1529. doi: 10.1021/acschemneuro.7b00050. Epub 2017 Mar 30.
4
In Vivo and In Vitro Characterization of a Novel MAO-B Inhibitor Radioligand, 18F-Labeled Deuterated Fluorodeprenyl.
J Nucl Med. 2016 Feb;57(2):315-20. doi: 10.2967/jnumed.115.161083. Epub 2015 Nov 19.
5
Kinetic modeling of the monoamine oxidase B radioligand [¹¹C]SL25.1188 in human brain with high-resolution positron emission tomography.
J Cereb Blood Flow Metab. 2014 May;34(5):883-9. doi: 10.1038/jcbfm.2014.34. Epub 2014 Feb 12.
6
PET radiopharmaceuticals for probing enzymes in the brain.
Am J Nucl Med Mol Imaging. 2013 Apr 9;3(3):194-216. Print 2013.
7
Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies.
J Cereb Blood Flow Metab. 2013 Jun;33(6):863-71. doi: 10.1038/jcbfm.2013.19. Epub 2013 Feb 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验